CD22 and acute lymphoblastic leukemia: Fousek et al. (172) constructed CD19/CD20/CD22 TriCAR T-cells that manifested strong killing activity on both ALL cells and CD19-negative relapsed cells in vitro and in murine models, while CD19 CAR T-cells were ineffective.